Tacrolimus for Myasthenia Gravis

Kim, Yool-hee; Shin, Ha Young

Review article

Korean Journal of Neuromuscular Disorders 2016;8(1):39-42.

Yool-hee Kim, Ha Young Shin

Department of Neurology, Yonsei University College of Medicine, Seoul, Korea

중증근무력증과 타크롤리무스

김율희, 신하영

연세대학교 의과대학 신경과학교실

Abstract

Myasthenia gravis is an autoimmune disorder affecting neuromuscular junction. Corticosteroid and other immunosuppressive agents are used for the treatment of myasthenia gravis. Tacrolimus may also have a potential role in long-term supression of the immune system. There are limited but promising data to suggest beneficial effects of tacrolimus to control myasthenia gravis and to reduce corticosteroid burden. To date, the largest randomised controlled trial could not demonstrate significant differences in their primary endpoint. Therefore, additional well designed and high quality studies are necessary to determine the effects of tacrolimus on myasthenia gravis.